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Abstract  
The myocardium is a critical target in systemic immune-mediated diseases (SIDs), even in 
asymptomatic patients, with negative prognostic implications. This multidisciplinary position paper 
from the European Society of Cardiology (ESC) Working Group on Myocardial and Pericardial 
Disease focuses on inflammatory and degenerative myocardial diseases. Their type and frequency 
markedly differ in individual SIDs, thus here a disease-specific approach has been used. However, 
some general considerations and recommendations have been made. It is hoped that this document 
will provide a first orientation to cardiologists and non cardiology physicians in selecting an 
appropriate multidisciplinary diagnostic work-up in SIDs-related myocardial disease, as well as 
personalised treatment, setting the stage for future controlled studies. 
Key words: myocarditis; cardiomyopathy; immune-mediated disease; autoimmunity. 
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Introduction 	
Systemic immune-mediated diseases (SIDs) include autoimmune and autoinflammatory diseases 
affecting at least two-organ systems.1 Autoinflammatory diseases refer to a growing family of 
conditions characterised by episodes of unprovoked inflammation in the absence of high 
autoantibody titers or auto reactive T lymphocytes, reflecting a primary innate immune system 
dysfunction.1 Conversely, autoimmune diseases are characterised by aberrant B, T and dendritic cell 
responses, leading to a break in tolerance against self-antigens, with predominantly cell-mediated or 
autoantibody-mediated responses in genetically susceptible individuals.2-11 Autoantibodies (AAbs), 
when detectable, can promote inflammatory responses via immune complex formation and may 
directly affect target organ function,10 e.g. resulting, in cardiac autoimmunity, in electrical 
disturbance, cardiomyocyte dysfunction or loss and heart failure.12-15  However, a dichotomous 
classification does not reflect clinical evidence and a continuum from purely autoinflammatory to 
purely autoimmune diseases should be considered (Figure 1).1  
Cardiac involvement in SIDs is associated with adverse outcomes.16-18 Currently there is a lack of 
up to date cardiological diagnostic work-up in the scientific literature and in clinical practice, 
leading to poor scientific knowledge, late recognition or under diagnosis and under treatment of 
cardiac involvement.16-18  Specific limitations include the use of scores only based on clinical 
findings (e.g. heart failure symptoms) to stratify patients with cardiac involvement as well as 
limited information based on state-of-the art non-invasive and invasive methodology.16-18 Although 
all heart structures may be affected (Suppl Table 1 online), we will focus on inflammatory and 
degenerative myocardial diseases, which may include: 1) myocarditis evolving to a dilated 
cardiomyopathy (DCM) or a hypokinetic non-dilated cardiomyopathy; 2) endomyocarditis and 
endomyocardial fibrosis.19-22 The aim of this multidisciplinary position paper by the European 
Society of Cardiology (ESC) Working Group on Myocardial and Pericardial Disease is to help 
cardiologists and non-cardiac specialists to select the appropriate diagnostic work-up in SIDs, 
setting the stage for future therapeutic choices.11, 23-27  
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General approach to diagnosis of myocardial involvement in SIDs 
The type and frequency of myocardial involvement markedly differ in the main SIDs, making a 
general diagnostic algorithm too cumbersome to be clinically useful; therefore here a disease-
specific approach has been used. However, some general considerations and recommendations can 
be made.   
Clinical features suggesting myocardial involvement 
• Clinical presentation of myocarditis is unspecific. Red flags may include: unexplained 
dyspnoea, palpitations, chest pain with or without increased troponin, syncope, arrhythmia 
and acute or chronic congestive heart failure, sudden cardiac death, fulminant cardiogenic 
shock.22 
• Since in many SIDs accelerated coronary artery disease (CAD) as well as coronary 
microvascular dysfunction may be predominant or contributory to cardiac signs and 
symptoms,28 an ischaemic aetiology should be ruled out first, whenever clinically indicated, 
by standard non-invasive and invasive means.22, 28-29 The specific work-up should be 
tailored to the individual case and clinically oriented. 
Biomarkers, ECG, old and new imaging techniques 
• An increase in troponin and/or NT-pro BNP may be indicative of myocardial involvement, 
regardless to its aetiology.22 In addition troponin may be increased in extracardiac disease 
(e.g. pulmonary embolism). 22, 29 Conversely myocarditis may occur in the absence of 
troponin release.22 
• Some disease-specific biomarkers, e.g. AAbs,8-11 are available for the various SIDs and are 
part of the multiparametric diagnostic criteria (see section on specific SIDs), but so far it is 
unknown whether they may be markers associated with myocarditis. 
• Myocarditis may occur in association with any unexplained abnormality on standard 12 lead 
electrocardiography (ECG) or twenty-four hour-ECG Holter monitoring.22 
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• Cardiological non-invasive imaging plays a pivotal role in the detection of myocardial 
involvement in SIDs, although findings are often unspecific in relation to aetiology (Suppl. 
Table 2 online). The first-line method is standard echocardiography with Doppler analysis30-
32 as well as advanced methods, e.g. deformation imaging, to detect subclinical myocardial 
involvement.33-34 Echocardiography is also essential in the diagnosis of pericardial and 
valvular involvement.35-38 Transesophageal echocardiography particularly in association 
with 3D imaging may be useful in particular cases, such as Libman-Sacks endocarditis in 
systemic Lupus Erythematosus (SLE).39-40 The assessment of tricuspid and pulmonary 
regurgitation gradients plays a key role in noninvasive diagnosis of pulmonary hypertension 
(PH).40-41 
•  Other non-invasive techniques, in particular cardiac magnetic resonance (CMR) imaging 
with tissue characterisation sequences and positron emission tomography (PET) may refine 
the clinical suspicion of non-ischaemic inflammatory myocardial involvement, and help in 
the patient’s follow-up and in assessing response to treatment. CMR provides 
complementary information and is particularly useful when echocardiography is 
inconclusive. Cardiac involvement in SIDs can be assessed by CMR tissue characterisation 
with T1 and T2 weighted imaging and late gadolinium enhancement (LGE), as well as with 
parametric mapping. The characteristic subepicardial or midmyocardial LGE pattern seen in 
SIDs allows differential diagnosis from CAD and has been shown to correlate with disease 
activity in rheumatoid arthritis (RA),42 and in systemic sclerosis (SSc).43-44 CMR with LGE 
and T1 mapping can also identify early changes in SSc and RA.45, 46 Myocardial perfusion 
CMR abnormalities have been reported to correlate with C–reactive protein (CRP) in SSc.44 
• Computed Tomography (CT) is mainly used for the diagnosis of aortic disease and coronary 
atheroma as well as pericardial disease, if other tests fail to provide sufficient information. 
CT shows coronary and aortic calcification, which is more prevalent and severe in RA than 
in controls 47. In patients at low and intermediate risk with symptoms and/or ventricular 
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dysfunction, CT coronary angiography may substitute invasive coronary angiography. CT 
can also be used as an adjunct to echocardiography in PH work-up.41  
• Positron Emission Tomography (PET) is particularly useful to detect inflammation in 
specific settings, such as sarcoidosis.16, 48  Myocardial perfusion PET, using short-lived 
radionuclides such as 13N-NH3, offers noninvasive quantitation of myocardial blood flow 
(MBF). Abnormal MBF is a strong predictor of adverse outcome in CAD, reflecting 
microvascular dysfunction and impaired coronary flow reserve.49  
•  Endomyocardial biopsy (EMB) is the gold standard for suspected myocarditis with or 
without associated SIDs; using current histological, immunological, immunohistochemical 
and molecular tools, it provides differentiation between infectious and non-infectious 
myocarditis.22, 50-55 In addition it can identify cardiac vasculitis and/or other non- 
inflammatory (degenerative or infiltrative) myocardial diseases applying special histological 
and immunohistochemical techniques (Figures 2-3).22, 50-55  It may be particularly useful at 
diagnosis in SIDs if cardiac clinical, non-invasive and invasive findings suggest non-
ischaemic myocardial involvement as well as if there is an unexplained and unexpected 
change in cardiac status and the histological confirmation is expected to change 
management. This is especially true if the diagnosis cannot be made with biopsies of more 
accessible tissues, e.g. in cardiac amyloidosis.52-55 The clinical drawbacks of the method 
include low complication rate (0-0.8% of serious events) in experienced hands56-59 and 
sampling errors. For histology and immunohistochemistry at least three myocardial tissue 
samples from the right or left ventricle should be investigated,22,50 immediately fixed in 4%  
buffered formaldehyde for all histological and immunohistochemical stainings and for 
special stains of storage diseases. Additionally, at least two samples (fixed in RNA later or 
snap-frozen in liquid nitrogen and stored at -80°C) should be obtained for molecular 
analyses including cardiotropic viruses and bacteria by Reverse Transcription (RT-) 
polymerase chain reaction (PCR) detection.22, 50 
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• Ideally and whenever possible sophisticated and expensive second-step cardiac tests, e.g. 
CMR, PET, EMB should be performed in specialised centres, experienced in rare cardiac 
disease assessment. 
Recommendation 
1. Echocardiography should be performed in all SIDs patients with suspected cardiac 
involvement.30-38 CMR should be considered in uncertain cases and where myocarditis or 
myocardial infiltration is suspected.42-46 PET is particularly useful to detect inflammation in specific 
settings, such as sarcoidosis.16, 48 
2. EMB has significant clinical value,22, 50-55 provided that it is taken by experienced investigators 
and assessed by trained cardiopathologists from specialised laboratories, possibly certified by 
international organizations in terms of performance and interpretation of up-to date techniques. 
3. EMB may foster treatment decisions on the basis of histopathological results, particularly in 
eosinophilic myocarditis, sarcoidosis and in giant cell myocarditis (GCM).22, 50-55 In these types of 
non-infectious myocarditis, immunosuppressive therapy should always be considered, provided that 
major contraindications are excluded (e.g. active or latent malignancy or extracardiac infection).22  
4.The use of biomarkers, such as natriuretic peptides should be adapted according to current ESC 
heart failure guidelines, algorithms and cut-off values.92 It should not be done routinely but only if 
clinical suspicion of cardiac symptoms and/or signs, e.g. dyspnea, develop.92 
General principles of management of myocardial involvement in SIDs 
Since type and frequency of cardiac and specifically myocardial involvement are different in 
various SIDs, a detailed general management algorithm is not realistic, however some general 
principles can be addressed. Although all heart structures can be involved in SIDs, here we focus on 
myocardial inflammatory involvement that is under diagnosed and overlooked. Thus, there is also a 
lack of robust evidence-base for management of affected patients. 
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Role of disease specific therapies. 
Background disease specific therapies in SIDs include immunosuppressive and/or 
immunomodulatory regimes, particularly in active phases of the disease.11, 25 There is wide 
variability in clinical presentation, response to treatment and prognosis in SIDs,11 therefore 
immunosuppressive therapy is tailored to the level of disease activity, the involvement of vital 
organs and the presence of comorbidities, thus requiring a personalised approach targeted to reach 
the lowest level of disease activity, e.g. treat-to-target strategy.60 Anyway, when a vital organ 
failure ensues general supportive management is used, e.g. heart failure or kidney failure therapy. In 
many SIDs, proven myocarditis is an indication to a more intensive immunosuppression, since it 
may lead to irreversible organ damage and directly affect survival.16, 48, 61-72  
Complications of treatment 
Main immunosuppressive treatment complications include a higher incidence of acquired infections 
and/or reactivation of latent or opportunistic infections. The use of corticosteroids, in particular, is 
associated with adverse cardiovascular outcomes and an unfavourable metabolic profile.73 
Therefore, steroid-sparing strategies are preferred, especially if a chronic immunosuppressive 
regimen is needed.11 In addition, teratogenic and oncogenic effects of some immunosuppressants, 
e.g. methotrexate or mycophenolate mofetil, should be minimized and active screening programs 
are advisable in this high-risk population.   
Systemic Lupus Erythematosus (SLE) 
Heart involvement in SLE is common (more than 50% of the patients) and may affect any heart 
structure (Table 1).74  SLE myocarditis, which may be associated with mutations in the gene 
encoding the 3'-5' DNA exonuclease TREX1,75-76 had an autopsy frequency of up to 8% in the era 
of corticosteroids and chloroquine and hydroxychloroquine use.73 It is nowadays presumed to be 
rare, possibly in relation to better immunosuppressive regimens.11 Clinical presentation of SLE 
myocarditis is unspecific and difficult to be recognised, particularly when SLE diagnosis is not yet 
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established (Suppl. Table 3 online).77-78 The pathogenesis of SLE myocarditis is thought to be 
immune complex-mediated, with granular complement and immunoglobulin deposits seen at 
autopsy and on EMB.  Noninvasive diagnostic red flags include an unexplained increase in troponin 
I and/or NT-pro BNP,79 global or segmental hypokinesis on transthoracic (TTE) echocardiography. 
CMR imaging may detect abnormalities even in pre-clinical stages of SLE,  showing a non-
ischaemic pattern of myocardial LGE and/or oedema.79 Since accelerated atherosclerosis is well 
known to occur in SLE, CAD must be ruled out.28-29 EMB differentiates SLE myocarditis from the 
rare finding of chloroquine/hydroxychloroquine-induced cardiomyopathy and/or the common 
coronary vasculitis/vasculopathy.78, 80  Treatment of SLE myocarditis with high-dose 
methylprednisolone pulse is typically required, followed by oral corticosteroids in combination with 
immunosuppressive drugs, such as azathioprine, cyclophosphamide or intravenous immunoglobulin 
(IVIg).61 SLE patients are at high risk of infection due to the disease itself, which may be associated 
with primary immunodeficiency81 and to immunosuppressive treatment, leading to secondary 
immunodeficiency. Thus, ruling out infectious myocarditis by EMB may be clinically useful.22  
Recommendation   
4. EMB, applying histology, immunohistology and (RT-) PCR for detection of infectious agents, 
may be useful for diagnosis of SLE myocarditis, since SLE patients are at high risk of infection due 
to the disease itself and to immunosuppressive treatment.22, 81 
Systemic sclerosis (SSc) 
Heart involvement in SSc may be primary or secondary to concomitant kidney and/or pulmonary 
vascular/interstitial disease (Table 2, Suppl. Table 4 online).82 Primary myocardial involvement is 
often clinically occult and, when symptomatic, prognosis is poor. It may be related to dysfunction 
and/or structural damage of the microvascular bed, leading to repeat focal ischaemic injury and 
irreversible myocardial fibrosis,83 but it can also be due to a primary systemic myositic disease.84 
Left ventricular systolic dysfunction (LSVD) is the ‘hallmark’ of primary SSc myocardial 
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involvement.85 Routine echocardiography is clinically useful in diagnosing LVSD, as well as 
advanced echocardiography, e.g. tissue-doppler and speckle-tracking strain analysis, in heart failure 
with preserved ejection fraction (HFpEF).86-87 Left ventricular diastolic dysfunction (LVDD) is 
common;86-87 pulmonary hypertension (PH) should be carefully ruled out.41 Standard 12 lead ECG 
is abnormal in 50% of patients, the most common abnormality being left bundle branch block 
(16%), followed by first-degree (8%), or advanced atrioventricular (A-V) blocks (<2%).88  Twenty-
four hour-ECG Holter monitoring may detect supraventricular and/or ventricular arrhythmias; QTc 
prolongation may be associated with life-threatening tachyarrhythmias.89 SSc is perceived as having 
a high arrhythmic burden, with a 5% sudden death rate in patients with both skeletal and cardiac 
muscle disease.90  Clinical and non-invasive myocarditis red flags are similar to those seen in SLE, 
including unexplained increased (more than 3 fold) CPK or troponin,91 LVSD and/or LVDD,85-87 
non-ischaemic abnormal CMR tissue patterns.65 Autoimmune myocarditis (Figure 3) should be 
managed by immunosuppressive treatment,22, 62-65 while heart failure, arrhythmia and conduction 
disturbances should be treated according to current ESC guidelines.92-93 
Recommendation 
5. Referral to a cardiologist for further diagnostic work-up is indicated at any time in the screening 
of SSc patients, if myocardial involvement is suspected based upon clinical and noninvasive 
diagnostic findings.22, 62-65,84-89,91 
6. EMB may be considered in patients with clinically suspected myocarditis; immunosuppressive 
treatment is indicated in EMB-proven infection-negative myocarditis.22,62,65,84 
Sarcoidosis  
Sarcoidosis is a multisystem disorder of unknown cause(s), frequently presenting with hilar 
lymphadenopathy, pulmonary infiltration, ocular and skin lesions, mainly occuring in the 2nd to 5th 
decade (Suppl Table 5 online).94-95 The diagnosis is based upon clinical and non-invasive findings, 
supported by histological evidence of non-necrotising granulomas.  Cardiac involvement can be 
found in 2-7% of patients,48 but it may be underestimated: autopsy studies reported myocardial 
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granulomas in 20-30% of patients. The disease may present with sudden death, particularly in 
patients aged over 40 years, as well as with “idiopathic” A-V block of various degrees, or 
ventricular tachycardia in apparently healthy subjects.48, 94-95 Arrhythmogenic right ventricular 
cardiomyopathy is high on the list for differential diagnosis.48, 94-95 In Japanese patients heart 
involvement accounts for 50-85% of the deaths compared to 13-20% in Caucasians, confirming that 
racial factors may play a role in disease expression.16  
Sarcoid granulomas may involve any site of the heart, although left ventricular free wall, posterior 
interventricular septum, papillary muscles, right ventricle and the atria are most frequently affected. 
Heart involvement may occur at any time and does not correlate with other extracardiac locations. It 
should be suspected if a patient with known sarcoidosis develops conduction blocks, 
tachyarrhythmia, congestive cardiac failure, pericarditis or DCM (Table 3). The extension of 
myocardial granulomatosis is directly related to bad prognosis.16  Non-invasive imaging is indicated 
in all patients with suspected cardiac sarcoidosis and the definitive diagnosis of cardiac involvement 
requires a combined approach, often including CMR and PET (Table 3) (Figure 4). EMB may be of 
clinical value, but, since the myocardium is involved in a patchy fashion, its sensitivity may be low 
due to sampling error. If positive, EMB provides histological and aetiological differential diagnosis 
from idiopathic GCM and other infectious granulomatous forms (e.g. mycobacteria, Bartonella 
henselae, Toxoplasma gondii and Yersinia) (Figure 2).16 Corticosteroids are the gold standard 
treatment,16, 48 although response to medical therapy is variable and cardiac transplantation may be 
the last option (Table 4).  
Recommendation    
7. Red flags for cardiac involvement in clinically suspected or known extracardiac sarcoidosis, 
include: 
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- unexplained brady or tachyarrhythmia, heart failure signs and symptoms, LVDD and/or 
LVSD on echocardiography or CMR, and/or abnormal tissue patterns on CMR or FDG-PET 
uptake16,48,94-95 
- unexplained steroid-responsive cardiomyopathy16,48,94-95 
8. Corticosteroids are the first line treatment.16, 48 Other immunosuppressive drugs may be valid 
alternatives (Table 4).16, 48  
9. Internal cardioverter defibrillator (ICD) implantation may be considered earlier in patients with 
cardiac sarcoidosis who had haemodynamically compromising sustained ventricular arrhythmia or 
aborted cardiac arrest, if survival >1 year with good functional status can be expected. The most 
effective antiarrhythmic drugs are β-blockers, sotalol and amiodarone. Catheter ablation of 
ventricular arrhythmia is usually considered after an ICD implantation or failure of antiarrhythmic 
drug therapy. Primary and secondary sudden cardiac death prevention should be in keeping with 
current ESC guidelines.93, 96 
10. A-V block is the most frequent conduction abnormality in cardiac sarcoidosis and pacemaker 
therapy is often needed.93, 96 Corticosteroids may improve A-V node recovery, but pacemaker 
implantation may be preferable, even if the A-V block reverses transiently.16, 93, 96 
Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) 
EGPA is a rare eosinophilic-rich and necrotizing granulomatous vasculitis often involving the 
respiratory tract and predominantly affecting small to medium vessels (Suppl. Table 6 online). 
17,97,98 Multiple cell types participate in the cellular immune response, including Th2, Th1 and Th17 
cells and activated B cells producing antineutrophilic cytoplasmic antibody (ANCA).17 The 
pathogenesis of EGPA is multifactorial: it can be triggered by exposure to allergens or drugs, but a 
genetic background has also been recognized.17, 99 EGPA involves various organs; the triad of the 
disease includes asthma, allergic rhinitis and marked peripheral blood eosinophilia (Suppl. Table 6 
online).98,99 EGPA belongs to the spectrum of ANCA-associated vasculitides (AAV), although 
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ANCA frequency (30-40% of cases) is lower than in other AAV.18, 66, 99 Two major clinical subsets 
have been identified, including ANCA-positive EGPA, with features of small-vessel vasculitis, and 
ANCA-negative, in which organ damage is mainly mediated by tissue eosinophilic infiltration.17, 99 
Myocardial involvement, in particular as endomyocarditis or endomyocardial fibrosis (up to 60% of 
cases, with endocavitary thrombosis in about 10%), or cardiomyopathy (up to 20%), is associated 
with high eosinophilic cell count and the absence of ANCA (Figures 2, 4).18,67 In eosinophilic 
EGPA associated myocarditis (Figure 2), long-term prognosis is poor,17 leading to a restrictive 
cardiomyopathy or DCM,17,67 which is an independent risk factor for death.18  
Cardiac screening should include laboratory assessment (CK-MB and troponin) and ECG, 
echocardiography and CMR. Echocardiography and/or CMR can detect regional wall-motion 
abnormalities, pericardial effusion (20% of cases) and intracavitary thrombi.18,67 Tissue 
characterization by CMR may show features suggestive for myocarditis and myocardial fibrosis 
(Figure 4). Coronary abnormalities should be ruled out by coronary angiography. EMB may 
provide diagnosis of EGPA myocarditis, particularly in ANCA-negative patients with early and/or 
predominant cardiac involvement.67 Diagnostic work-up should be aimed to the identification of 
other causes of hypereosinophilic syndromes with possible heart involvement (toxic, infectious, 
clonal, hypersensitivity).100,101 The standard therapeutic approach to EGPA is based on high-dose 
corticosteroids plus immunosuppressive agents, including cyclophosphamide.66-67	
Recommendation  
11. Red flags and cardiological diagnostic methods are identical to those of other SIDs.17, 67, 99 Heart 
involvement is typically associated with high eosinophilic counts and negative ANCA status.18, 67 
12. The diagnosis of EGPA myocarditis may reinforce the indication to immunosuppression.66,67 
Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis) 
GPA is a rare necrotizing granulomatous AAV, predominantly affecting small to medium vessels, 
which usually involves the upper and lower respiratory tract, but any other organ can be affected 
(Suppl. Table 7 online).97,98  Cardiac manifestations, such as pericarditis (35% of cases), coronary 
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arteritis (12%), cardiomyopathy (30%), arrhythmias (6%) and valvular lesions (6%) have been 
reported.102 However, the extent and type of cardiac involvement are still poorly defined and mainly 
based on the composite Birmingham Vasculitis Activity Score, which includes loss of pulses, 
valvular heart disease, cardiomyopathy, ischaemic cardiac pain, pericarditis, congestive heart 
failure, not confirmed by routine cardiology methods. Between 1957 and 2005, the French 
Vasculitis Study Group included 1108 patients with systemic necrotizing vasculitides, among them 
311 GPA patients.103 Cardiac involvement was diagnosed in 13% of GPA subjects and a 
multivariate analysis identified age, renal and cardiac failure as independent negative prognostic 
factors.103  Conversely, in the Vasculitis Clinical Research Consortium longitudinal multicenter 
cohort study including 517 GPA patients, cardiac involvement was found in only 3.3% of GPA 
subjects and was not associated with a higher rate of relapse or premature death.102 In a meta-
analysis of long-term follow-up data from 4 European clinical trials including 535 newly diagnosed 
AAV patients, of whom 53% GPA cases, cardiovascular involvement, found in a minority (5.7%) 
of patients, was independently associated with a higher risk of relapse.104 In the absence of 
immunosuppressive treatment, the outcome of GPA is nearly always fatal.104 The combination of 
immunosuppressant drugs including biologic agents such as rituximab has remarkably improved 
GPA prognosis.105 
Recommendation  
13.  Since cardiovascular GPA involvement may predict poor prognosis and/or higher risk of 
relapse,103,104 an upgraded immunosuppressive regimen may be considered.105 
Inflammatory myopathies (IM). 
IM are a heterogeneous group of diseases primarily affecting skeletal muscle, including 
dermatomyositis, polymyositis, necrotizing autoimmune myositis, inclusion-body myositis and 
overlap myositis, which are characterized by specific IM AAbs with features of the connective 
tissue disorders.106 Cardiac involvement in IM is clinically occult in most patients, but may be 
suspected by non-invasive cardiovascular methods68, 106-107 and is related to bad outcome.107-108 
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Myocarditis occurs in up to 30% of autopsied patients, with or without concomitant coronary or 
vessel vasculitis.106 Biopsy-proven lymphocytic or giant cell myocarditis may be found in IM 
patients with or without myositis-specific (anti- tRNA-synthetase) AAbs68,109-111 and is a negative 
prognostic factor.110, 69, 111 Red flags and cardiological diagnostic methods are identical to those in 
clinically suspected myocarditis in other SIDs.68, 106-107,111  Myocardial ischaemia (due to coronary 
vasculitis), pericardial or valve disease may also occur.107  Cardiovascular mortality ranges from 5-
17%, most frequently caused by myocardial infarction, heart failure and myocarditis.107  
Myocarditis seems to respond to an intensification of standard immunosuppression.69,107,109-111 
Recommendation  
14. Myocarditis may be found in IMs patients with or without myositis-specific Abs and it may be 
an indication to a more intensive immunosuppressive regimen.69,107, 109-111 
Rheumatoid arthritis (RA). 
RA exhibits a high risk of cardiovascular disease (CVD) and of heart failure, resulting in premature 
morbidity and mortality and reduced life expectancy compared to subjects without RA.112 Positive 
AAbs status, joint pain severity and conventional risk factors were all strongly associated with 
increased CVD risk.112 At present, accelerated atherosclerosis is considered a main complication, 
resulting from the cumulative effect of chronic systemic inflammation, oxidative stress and classical 
CVD risk factors.113 All cardiac structures can be affected in RA resulting in pericarditis (common, 
but symptomatic in less than 1%), myocarditis, myocardial fibrosis, brady- and tachyarrhythmia, 
epicardial CAD, valvular disease (usually a single valve, resulting mainly in regurgitation and 
rarely in stenosis), PH and cardiomyopathy.114-116 In 3-30% of patients the RA-associated 
cardiomyopathy may be caused by focal lymphocytic, diffuse necrotizing or granulomatous 
myocarditis.114, 116 The granulomas show a predilection for the left ventricle and are 
morphologically identical to the subcutaneous RA nodules (Figure 3).114 Recent CMR-based studies 
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suggest that RA myocarditis may be more prevalent than previously suspected, even in 
asymptomatic patients, but more correlative data with EMB are needed (Figure 4). 46 
Recommendation  
15. Since RA patients have a high burden of CVD, mainly because of accelerated 
atherosclerosis,112-113 a multidisciplinary management including a cardiologist is indicated and 
should be driven by a clinical suspicion from the attending  physician .  
Spondyloarthritis (SA) 
SA primarily affects joints and the axial skeleton and is associated with increased cardiovascular 
morbidity and mortality, although the contributory role of CVD risk factors and of anti-
inflammatory treatment needs to be further defined;117 in psoriatic arthritis, CVD is the leading 
cause of death (36.2%) and the death risk is 1.3 times greater than in the general population. 
Cardiovascular symptoms are present in 10% of AS patients and clinical presentations may include 
CAD, valvular disease, mainly aortitis and aortic insufficiency (1-34%), and conduction defects, 
anecdotally myocarditis.117-119.An association between disease activity and CVD risk has been 
suggested in AS, but statin therapy is still under scrutiny.120 
Myasthenia gravis (MG) 
MG is an autoantibody and T helper cell mediated autoimmune disease, most often associated with 
thymic hyperplasia or thymoma, less frequently (up to 8% of patients) with thyroid diseases, RA 
and SLE, affecting patients of either sex, at any age.70 Diagnosis is established by patient history, 
(e.g. fluctuating muscular weakness involving ocular, bulbar and, less frequently, nuchal or 
proximal limb muscles), electromyography and detection of AAbs interfering with the acetylcholine 
receptor (AChR).70 Patients without anti-AChR AAbs often have AAbs against the muscle-specific 
receptor tyrosine kinase and other postsynaptic neuromuscular junction components. In addition, 
AAbs against striated muscular antigens, such as anti-titin, anti-ryanodine and anti-Kv 1.4 AAbs, 
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can be detected almost exclusively in thymoma patients.121 In Japanese patients, anti-Kv 1.4 AAbs 
specifically correlate with severe MG, myasthenia crisis, myocarditis, and ECG abnormalities.122 
Cardiac involvement in MG may include Takotsubo cardiomyopathy, myocarditis, abnormal ECG 
findings such as QT-prolongation, anticholinesterase induced A-V block, and sudden cardiac 
death.122 Heart rate variability is disturbed, due to autonomic dysfunction123. Since coronary arteries 
dilate in response to acetylcholine, cases of diffuse coronary spasm associated with 
anticholinesterase therapy have been reported.124  Nevertheless, there is no association between MG 
and CAD. Takotsubo or stress induced cardiomyopathy is typically observed during myasthenia 
crisis episodes, older patients being at a higher risk.125 Myocarditis typically affects thymoma-
related elderly MG patients and is associated with skeletal muscle cross-reactive striational anti-
heart AAbs;122 diagnosis is often delayed because heart failure symptoms may be misinterpreted.  
Biopsy-proven GCM may be associated with MG and carries a worse prognosis, compared to other 
forms of myocarditis.71-72  
Recommendation  
16. The threshold for suspecting GCM should be low in MG, particularly in elderly patients and in 
those with skeletal muscle cross-reactive striational anti-heart AAbs. If GCM is clinically 
suspected, particularly in life-threatening heart failure and/or arrhythmias presentations, EMB is 
indicated.22, 51, 96 
17. MG patients with GCM myocarditis should be promptly treated with adequate 
immunosuppression according to the patient’s age and the clinical condition.22, 71-72 
Primary Sjögren Syndrome (SS) 
Primary SS is a chronic autoimmune exocrinopathy that mostly affects middle-aged women, 
leading to xerostomia and xerophtalmia.126 The diagnosis of primary SS requires an objective 
immunological abnormality, either focal lymphocytic infiltrates in the minor salivary glands, or the 
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presence of anti-SSA/SSB AAbs, which are present in 50 to 90% of cases, but are not specific for 
primary SS, being found in SLE or in other connective tissues diseases.126 In more than one third of 
cases, SS also involves extra glandular sites, such as lungs, kidneys, and joints. Fatigue is one of the 
most common symptoms.126 Only few isolated cases of clinically suspected myocarditis have been 
described in primary SS, one of which associated with cryoglobulinemic vasculitis.127-128 An 
echocardiographic study in 107 consecutive primary SS patients without cardiac symptoms and 112 
healthy controls, matched for age and gender, has shown a higher prevalence of valvulopathies, 
pericardial effusion, higher systolic pulmonary pressure, LVDD129.  
Congenital heart block (CHB) may be associated (2% of cases) with maternal AAbs against SSA 
(Ro) or SSB (La) proteins (neonatal lupus syndrome).130 Some infants with CHB, usually young 
(less than 2 year-old), or older (greater than 10 year-old), may develop endomyocardial 
fibroelastosis leading sometimes to heart failure despite early pacemaker implantation.131-132 This 
encourages a long follow-up of CHB children of mothers with anti-SSA/SSB AAbs. 
Recommendation  
18. Long follow-up of CHB children of mothers with anti-SSA/SSB AAbs is recommended.131-132 
Autoinflammatory diseases (AD)  
Monogenic AD usually start in infancy, most commonly involve the skin, serous membranes, 
joints, gastrointestinal tract, eyes and, less frequently, the nervous system; they are associated with 
elevated levels of acute phase reactants, e.g. CRP, but a relative lack of high titer AAbs or antigen-
specific T cells (Figure 1, Suppl. Table 8 online).133 Complications include severe inflammatory 
anaemia and AA amyloidosis, which usually does not affect the heart.133 
Nonhereditary polygenic AD include adult-onset Still’s disease (AOSD) and systemic-onset 
juvenile idiopathic arthritis (sJIA), as well as other immune-mediated conditions, such as Behçet’s 
disease, and inflammatory bowel disease (IBD) that overlap with autoimmune diseases.133-134 
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Among monogenic AD, Mediterranean fever (MF) and tumour necrosis factor receptor-associated 
periodic fever syndrome (TRAPS) occasionally may cause recurrent pericarditis, clinically 
suspected myocarditis has been anecdotally described only in TRAPS135. 
Myocarditis, usually a neutrophilic form, can be an uncommon complication of Behçet, AOSD and 
Crohn’s disease.135 GCM has been reported in association with Crohn’s disease and Behçet’s 
disease. 136,137  
Recommendation  
19. Myocarditis, although uncommon, should be suspected in some nonhereditary AD, such as 
Still’s disease and Behçet’s disease if cardiac red flags similar to other SIDs are present.136-137 
Conclusions 
The cardiovascular system and in particular the myocardium are often critical targets in SIDs, even 
in asymptomatic patients, leading to a relevant negative burden on prognosis. However, there are at 
present no studies to recommend cardiac screening in all patients regardless of the clinical 
suspicion. Therefore, management of patients with SIDs should always include prospective 
cardiological screening and follow-up in patients with clinically suspected cardiac involvement and 
when felt necessary by the attending physician. It is hoped that this document will provide a first 
orientation to cardiologists and non-cardiology physicians in selecting an appropriate 
multidisciplinary diagnostic work-up in SIDs-related myocardial disease, as well as personalised 
treatment. Furthermore, it is hoped that cardiologists will actively participate to conception and 
design of future immunosuppressive/immunomodulatory trials in well-characterized groups of SIDs 
patients with early/subclinical as well as established myocardial involvement. In fact, at present 
there is a relative paucity of evidence-based treat-to-target regimens in SIDs patients with 
myocardial involvement besides empirically driven intensification of conventional 
immunosuppression. 
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Figure legends. 
Figure 1. Classification of Systemic Inflammatory Diseases  
Adapted from reference 1. Abbreviations (see also text): ALPS, autoimmune lymphoproliferative 
syndrome; AOSD, adult-onset Still’s disease; APECED, autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy syndrome; CANDLE, Chronic atypical neutrophilic dermatosis 
with lipodystrophy and elevated temperature; CMRO, chronic multifocal recurrent osteomyelitis; 
DIRA, Deficiency of interleukin-1 receptor antagonist; DITRA, Deficiency of the interleukin-36-
receptor antagonist; FCAS, Familial cold autoinflammatory syndrome; FMF, familial 
Mediterranean fever; HIDS, hyperimmunoglobulinaemia D with periodic fever syndrome; HLA, 
human leukocyte antigen; IPEX, immune dysregulation, polyendocrinopathy, enteropathy, X-
linked; MAS,Macrophage activation syndrome; MHC, major histocompatibility complex; NOMID 
(also known as CINCA), Neonatal onset multisystem inflammatory disease; PAPA, pyogenic 
arthritis, pyoderma gangrenosum, and severe cystic acne; PFAPA, Periodic fever, aphthous 
stomatitis, pharyngitis and adenitis; TRAPS, tumour necrosis factor receptor–associated periodic 
fever syndrome 
Figure 2 and 3. EMB examples of myocarditis in SIDs. 
Typical examples of histologically and immunohistologically proven myocarditis in different SIDs 
(EGPA (a, x100), sarcoidosis (b, x100) in Figure 2, RA (c, x200) and SSc (d, x200) in Figure 3). As 
shown by Masson Trichrome stains fibrosis (blue areas) is present in all cases of myocarditis, 
indicating an ongoing or chronic inflammation, which is characterized by presence of T 
lymphocytes (CD3), macrophages (CD68) and major histocompatibility complex (MHC) class II 
expression. In addition, in EGPA a significant infiltration of eosinophilic granulocytes (Giemsa 
stain of B and D (D=inset of B)) is observed in presence of a severe necrotizing vasculitis. In 
sarcoidosis (b) numerous CD68+ MHCII expressing giant cells (C, D) are present within non-
caseating epithelioid granulomas. 
Figure 4: CMR findings in SIDs 
	 42	
Top, panel a. Late gadolinium enhanced CMR of a 38 year old patient with cardiac sarcoidosis. The 
images show the typical pattern of multiple focal areas of enhancement throughout the heart 
consistent with granulomatous infiltration.  
Middle, panel b. Late gadolinium enhanced CMR of a 54 year old patient with EGPA. Note the 
characteristic widespread subendocardial enhancement of the left ventricle. 
Bottom, panel c. Late gadolinium enhanced CMR of a 63 year old patient with long standing RA. 
There is midmyocardial enhancement in the basal infero-lateral wall as a unspecific sign of 
previous myocarditis.  
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Table 1: Cardiac involvement in Systemic Lupus Erythematosus74 
Cardiac involvement Presentation/ Clinical Frequency 
Pericardium Pericarditis /30% 
Myocardium and coronary 
vessels 
- Autoimmune Myocarditis /1% 
- CAD due to premature atherosclerosis / <1% 
- CQ/HCQ-induced cardiomyopathy / <1% 
- CAD due to coronary thrombosis associated to antiphospholipid 
AAbs < 1% 
- Small vessel vasculitis / <1% 
Endocardium - Valvular involvement / 10% usually associated to 
antiphospholipid AAbs 
- Libman-Sacks endocarditis Abs / <1% usually associated to 
antiphospholipid AAbs 
Cavities Thrombosis / < 1% usually associated to antiphospholipid AAbs 
Pulmonary arteries - Pulmonary arterial hypertension 
- Pulmonary hypertension related to pulmonary embolism usually 
associated to antiphospholipid AAbs 
Abbreviations: Abs= autoantibodies; CAD=coronary artery disease; CQ=chloroquine; HCQ= 
hydroxychloroquine. 
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Table 2: Cardiovascular involvement in systemic sclerosis (SSc)82,85 
Cardiac involvement Presentation/ Clinical Frequency Comments 
Reduced LVEF About 5%  High risk in: male gender, 
diffuse cutaneous SSc, history 
of digital ulceration, renal 
crisis and muscle involvement 
Reduced LV filling About 30%  Post-capillary PH: increasing 
occurrence 
Reduced RVEF 5-10% Related to PH but can also be 
related to primary heart 
disease and RV fibrosis 
Valvular abnormalities Similar frequency as matched controls  
Pericarditis 10 to 20% Usually mild, asymptomatic. 
When large, recurrent and/or 
symptomatic it reflects the 
disease progression with high 
risk of PH or renal crisis.  
Pulmonary arteries PH in about 5 to 10% Mainly late complication in 
limited cutaneous SSc and 
positive anti-centromere 
AAbs. Systematic annual 
screening recommended  
Myocarditis  To be suspected particularly in SSc 
patients with concomitant peripheral 
myopathy 
Usefulness of ECG Holter, 
troponin, cardiac MRI, EMB 
to confirm the diagnosis 
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Table 3. Diagnostic work-up in cardiac sarcoidosis16,48,96  
Test Findings Comments 
ECG • PR prolongation, fragmented QRS 
• A-V nodal block  
• atrial or ventricular premature beats 
It should be a part of the initial 
evaluation. 
Echocardiography • hypokinesis or dyskinesia; chamber 
enlargement, aneurysms 
• wall thinning and wall motion  
abnormalities 
• ventricular dilatation; depressed 
ejection fraction 
• valvular dysfunction; papillary 
muscle involvement  
• pericardial effusion 
Data may be not specific, but 
echocardiography may help to assess 
cardiac size and function at diagnosis 
and during follow-up. 
EMB • presence of granulomas is 
confirmatory of the diagnosis. 
• yield of EMB is low being only 
30% in initial biopsy 
• sampling using 18FDG -PET 
increases diagnostic yield 
Its sensitivity is low. In the absence 
of an alternative aetiology, 
sarcoidosis must be suspected in 
presence of heart dysfunction or 
ECG abnormalities, even if EMB is 
negative.  
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CMR 
 
• Gadolinium enhanced CMR can 
show patchy focal enhancement in 
regions with granulomatous 
myocardial infiltration.  
• T2 weighted CMR can show 
myocardial oedema in acute 
inflammatory myocardial 
involvement.	
Cine CMR shows similar findings as 
echocardiography. CMR can contribute 
unique information to the non-invasive 
diagnosis of cardiac sarcoidosis and is 
well suited to follow the course of cardiac 
involvement. It may also serve as a  
prognostic indicator for disease severity. 
PET/CT 
 
• Increased uptake of 18FDG occurs 
within activated macrophages and 
CD4+ T cells forming granuloma 
• Patchy and focal cardiac uptake is 
specific for sarcoidosis  
• Increased myocardial uptake most 
frequently observed in the basal 
and lateral LV wall  
PET represents a key method to evaluate 
cardiac areas involved by sarcoidosis. 
Pooled estimates demonstrated a 
sensitivity of 89% and specificity of 78%.  
 
 
Abbreviations: A-V=atrioventricular; CT= computed tomography; CMR=cardiac magnetic 
resonance; ECG=electrocardiography; EMB=endomyocardial biopsy; FDG-PET= 
fluorodeoxyglucose Positron Emission Tomography; LV=left ventricular 
 
  
	 47	
Table 4: Treatment of cardiac sarcoidosis16, 48, 96  
Medical and 
surgical therapy  
Modality Comments 
Corticosteroids • Pulse of iv methylprednisolone (500 mg daily)  
• Oral prednisone (initial dose ~ 1 mg/kg/ day)  
• Prednisone is gradually tapered to a 
maintenance therapy (5-10 mg/die) for 6-9 
months 
Steroids represent the gold 
standard therapy.  Randomized 
trials are lacking; thus, appropriate 
dose and duration have not been 
defined. 
Other medical 
therapies 
• hydroxychloroquine (400 mg/daily)  
• Methotrexate (10-20 mg weekly) 
• Azathioprine (100-150 mg daily) 
• Mycophenolate mofetil (1.0-2.0 gr daily) 
• Pulse of iv cyclophosphamide (500-1000 mg 
every 3-4 weeks) 
Randomized trials have not been 
done. Additional 
immunosuppressive treatment 
alone or together with steroids may 
represent an effective alternative 
therapy in aggressive cardiac 
sarcoidosis. 
Biologics • Infliximab 
• Adalimumab  
• Rituximab 
Data are insufficient to ensure the 
efficacy of biologics. Off-label 
biologics may be considered in 
subjects who do not respond to 
other therapies. A careful 
examination of the benefit/risk 
ratio must be considered before 
beginning such therapies. 
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Adjuntive cardiac 
therapy 
• Antiarrhythmics 
• Catheter ablation 
• Implantable Cardioverter Defibrillators (ICD) 
The efficacy of antiarrhythmic is 
variable. An ICD may be 
considered earlier (see 
recommendation 9). Ventricular 
tachycardia resistant to medical 
therapy and ICD may require 
ablation therapy.   
Surgical therapies • Surgical resection of ventricular aneurysms 
• Pericardiectomy 
• Heart transplantation 
Surgical resection of ventricular 
aneurysms or pericardium may be 
necessary in selected cases. 
Cardiac transplantation is the only 
option for patients with end-stage 
heart failure refractory to medical 
therapy.  
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Figure 1. Classification of Systemic Inflammatory Diseases  
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Figure 2. EMB examples of myocarditis in SIDs. 
 
 
Figure 3. EMB examples of myocarditis in SIDs. 
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Figure 4: CMR findings in SIDs 
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Supplementary Table 1 (online):  Diversity and estimated frequency of cardiac involvement in 
SIDs 
Cardiac involvement Presentation/ Clinical Frequency 
Systemic lupus erythematosus pericarditis 30%, myocarditis 1%, valvular involvement 10%, 
endocarditis <1% 
Systemic sclerosis reduced left ventricular ejection fraction (LVEF) 5%, diastolic 
dysfunction 30%, reduced right ventricular ejection fraction (RVEF ) 
5-10%, pericarditis 10-20%, reports on myocarditis     
Sarcoidosis clinical (arrhythmias) 5-7%; granulomas in autopsy 20-30% 
Eosinophilic granulomatosis 
with polyangiits 
endomyocarditis, endomyocardial fibrosis up to 60%, 
cardiomyopathy 20% 
Granulomatosis with 
polyangiitis 
pericarditis 35%, coronary arteritis 12%, cardiomyopathy 30%, 
arrhythmias 6%, valvular lesions 6% 
Inflammatory myopathies myocarditis in up to 30% of autopsies 
Rheumatoid arthritis main complication: accelerated atherosclerosis; cardiomyopathy or 
myocarditis 3-30%, all cardiac structures may be affected 
Ankylosing spondylitis cardiovascular disease as leading cause of death 36% in psoriatic 
arthritis, valvular disease 1-34%, anecdotally myocardits 
Myasthenia gravis reports on cardiomyopathy, giant cell myocarditis 
Sjögren syndrome reports on valvulopathies, pericardial effusion, arrhythmias 
Auto-inflammatory disease pericarditis, reports on myocarditis 
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Supplementary Table 2 (online): Overview of imaging methods to assess cardiovascular 
involvement in SIDs.  
 Myocardial 
contractile  
function 
LV/RV
mass 
Scar/ 
Fibrosis 
Ischaemia Valve 
involvement 
Pericardial 
involvement 
Aortic 
involvement 
Echo ++ ++ - ++ ++ ++ + 
CMR ++  ++  ++ ++ + ++ ++ 
CT + ++ + + + ++ ++ 
Nuclear 
Imaging 
+ + + ++ - - _ 
 
- no indication  
+ limited indication  
++ strong indication 
 
Abbreviations: CMR=cardiac magnetic resonance; CT=computed tomography; 
Echo=echocardiography.  
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Supplementary Table 3 (online): The diagnosis of Systemic Lupus Erythematosus: 
Updated American College of Rheumatology Classification Criteria for SLE 77 
Criterion* Definition 
1. Malar rash Fixed, flat or raised erythema over the malar eminences, tending to spare the nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging (older lesions 
may demonstrate atrophic scarring) 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by a physician 
5. Arthritis Nonerosive arthritis involving at least 2 peripheral joints, characterized by tenderness, swelling, 
or effusion 
6. Serositis (A) Pleuritis: Convincing history of pleuritic pain or rub heard by a physician or evidence of 
pleural effusion 
or 
(B) Pericarditis: Documented by ECG or rub or evidence of pericardial effusion 
7. Renal disorder (A) Persistent proteinuria >0.5 g/day or >3+ if quantitation not performed 
or 
(B) Cellular casts: May be red blood cell, hemoglobin, granular, tubular, or mixed 
8. Neurologic 
disorder 
(A) Seizures: In the absence of offending drugs or known metabolic derangements (eg, uraemia, 
ketoacidosis, electrolyte imbalance) 
or 
(B) Psychosis: In the absence of offending drugs or known metabolic derangements (eg, uraemia, 
ketoacidosis, electrolyte imbalance) 
9. Hematologic (A) Hemolytic anaemia: With reticulocytosis 
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disorder or 
(B) Leukopenia: < 4000/mm3 total on =2 occasions 
or 
(C) Lymphopenia: < 1500/mm3 on =2 occasions 
or 
(D) Thrombocytopenia: < 100,000/mm3 in the absence of offending drugs 
10. Immunologic 
disorder 
(A) Anti-DNA: Antibody to native DNA in abnormal titer 
or 
(B) Anti-Sm: Presence of antibody to Smith (Sm) nuclear antigen 
or 
(C) Positive finding of antiphospholipid antibodies based on (1) an abnormal serum level of IgG 
or IgM anticardiolipin antibodies, (2) a positive test result for lupus anticoagulant using a 
standard method, or (3) a false-positive serologic test for syphilis known to be positive for =6 
months and confirmed by Treponema pallidum immobilization or fluorescent treponemal 
antibody absorption tests 
11. Antinuclear 
antibody (ANA) 
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any 
point in time and in the absence of drugs known to be associated with drug-induced lupus 
syndrome 
Abbreviations: ECG = electrocardiogram; Ig = immunoglobulin; SLE = systemic lupus erythematosus 
*=SLE can be diagnosed if any 4 or more of the following 11 criteria are present, serially or 
simultaneously, during any interval of observation. 
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Supplementary Table 4 (online): Systemic sclerosis (SSc) 2013 ACR/EULAR classification82 
Item* Sub-item(s) Weight/Score 
Skin thickening of the fingers of both hands extending 
proximal to the metacarpophalangeal joints (sufficient 
criterion) 
  –  9 
Skin thickening of the fingers (only count the higher 
score) 
Puffy fingers 
Sclerodactyly of the fingers 
(distal to the metacarpo-
phalangeal joints but proximal 
to the proximal 
interphalangeal joints) 
2 
4 
Fingertip lesions (only count the higher score)  Digital tip ulcers  
Fingertip pitting scars  
2 
3 
Telangiectasia  –  2 
Abnormal nailfold capillaries  –  2 
Pulmonary arterial hypertension and/or interstitial lung 
disease (maximum score is 2) 
Pulmonary arterial 
hypertension 
Interstitial lung disease 
2 
2 
Raynaud‘s phenomenon  –  3 
SSc-related autoantibodies (anticentromere, anti-
topoisomerase I [anti-Scl-70], anti-RNA polymerase III) 
(maximum score is 3) 
Anticentromere 
Anti-topoisomerase I 
Anti-RNA polymerase III 
3 
* These criteria are applicable to any patient to include in an SSc study. The criteria are not applicable to 
patients with skin thickening sparing the fingers or having a scleroderma-like disorder that better explains 
their manifestations (e.g., nephrogenic sclerosing fibrosis, generalized morphea, eosinophilic fasciitis, 
scleredema diabeticorum, scleromyxedema, erythromyalgia, porphyria, lichen sclerosis, graft-versus-host 
disease, diabetic cheiroarthropathy).  The total score is determined by adding the maximum weight (score) in 
each category. Patients with a total score of ≥9 are classified as having definite SSc. 
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Supplementary Table 5 online: Main extracardiac features of sarcoidosis94-95 
________________________________________________________________________________ 
Acute sarcoidosis 
• General concepts: the acute onset is characterised by the triad of erythema nodosum, 
arthritis and hilar lymphadenopathy (Lofgren’s syndrome) 
• Epidemiology: commonly recognised in Caucasians, especially Scandinavians, aged about 
25 years, and in pregnant or lactating women. 
Chronic sarcoidosis 
• General concepts: an insidious onset is usually followed by relentless, progressive fibrosis 
at all diseased sites. 
• Epidemiology: multisystem disease occurring more frequently in some ethnic groups. 
• Main organ involvements 
o Lung (about 80-90% of patients): Dyspnoea, dry cough, or chest discomfort are 
usual symptoms. Conventional radiography need to be complemented by high 
resolution CT scanning. Pulmonary function tests usually reveal a restrictive defect 
and a lowered TLCO/KCO 
o Skin: Skin lesions include erythema nodosum, lupus pernio, granuloma annulare, 
plaque, maculopapular eruptions scars and keloids. 
o Eyes: anterior and posterior uveitis may be present. Other ocular findings include 
choroidoretinitis, periphlebitis retinae; retinal, macular and optic nerve oedema and 
retinal haemorrhage. 
_______________________________________________________________________________ 
Abbreviations: CT= computed tomography; TLCO/KCO= transfer factor for carbon monoxide/ "volume–
corrected" value of TLCO. 
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Supplementary Table 6 (online): The diagnosis of eosinophilic granulomatosis with 
polyangiits (EGPA): Classification criteria by the 2012 Chapel Hill Consensus conference and 
the 1990 American College of Rheumatology (ACR)97-98  
1990 ACR criteria for 
classification   
of Churg-Strauss-
Syndrome97 
Churg-Strauss syndrome if at least 4 of these 6 criteria are 
positive.* 
The presence of any 4 or more of the 6 criteria yields a sensitivity 
of 85% and a specificity of 99.7% 
 Asthma 
 Eosinophilia > 10% 
 Neuropathy (mono or poly) 
 Pulmonary infiltrates, non-fixed 
 Paranasal sinus abnormality 
 Extravascular eosinophils 
2012 CHCC statements for 
the  
definition of EGPA98 
 
 Eosinophil-rich and necrotizing granulomatous inflammation often 
involving the respiratory tract and necrotizing vasculitis 
predominantly affecting small to medium vessels and associated with 
asthma and eosinophilia 
 Nasal polyps are common 
 ANCA is more frequent when glomerulonephritis is present. 100% 
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with documented necrotizing glomerulonephritis have ANCA 
 Limited expressions of EGPA confined to the upper or lower 
respiratory tract may occur. 
 Granulomatous and nongranulomatous extravascular inflammation, 
such as nongranulomatous eosinophil-rich inflammation of lungs, 
myocardium, and gastrointestinal tract, is common. 
*Three overlapping phases of EPGA that progress at variable intervals have been described: In the 
first stage, nonallergic eosinophilic asthma and other allergy symptoms such as rhinosinusitis and/or 
nasal polyposis are the defining feature. The second phase is characterized by tissue and blood 
eosinophilia. In the third phase, the characteristic findings are eosinophilic infiltration in tissue, 
eosinophilic vasculitis of the small arteries and veins, and eosinophilic granulomas.  
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Supplementary Table 7 (online): The diagnosis of granulomatosis with polyangiitis (GPA): 
classification criteria by the 2012 Chapel Hill Consensus conference and the 1990 American 
College of Rheumatology (ACR)97-98  
1990 ACR criteria for GPA classification 97 Leavitt  
 Wegener’s granulomatosis is defined by the 
presence of at least 2 of the following 4 criteria 
(sensitivity of 88.2% and a specificity of 92.0%):  
 abnormal urinary sediment (red cell casts or greater 
than 5 red blood cells per high power field) 
 abnormal findings on chest radiograph (nodules, 
cavities, or fixed infiltrates) 
 oral ulcers or nasal discharge 
 granulomatous inflammation on tissue biopsy 
2012 CHCC statements for GPA definition98  
 Necrotizing granulomatous inflammation and 
necrotizing vasculitis associated with 
antineutrophil cytoplasmic antibody (ANCA). 
 Predominantly small to medium vessels (e.g., 
capillaries, venules, arterioles, arteries and veins) 
are affected. 
 The upper and lower respiratory tract is usually 
involved.  
 Necrotizing glomerulonephritis is common. 
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 Ocular vasculitis and pulmonary capillaritis with 
hemorrhage are frequent. 
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Supplementary Table 8 (on-line). The expanding spectrum of autoinflammatory diseases 
________________________________________________________________________________
Monogenic syndromes: 
• Familial Mediterranean fever (FMF) 
• Tumour necrosis factor receptor-associated periodic syndrome (TRAPS) 
• Hyper-IgD syndrome (HIDS) 
• Cryopyrin-associated periodic syndromes (CAPS): Familial cold autoinflammatory 
syndrome, Muckle-Wells syndrome, Neonatal onset multisystem inflammatory 
disease/chronic Infantile neurologic cutaneous arthropathy syndrome (NOMID/CINCA) 
• Juvenile systemic granulomatosis (Blau syndrome, early onset sarcoidosis) 
• Syndrome of pyogenic arthritis, pyoderma gangrenosum and acne (PAPA syndrome, 
PAPAS, PAPGA syndrome) 
• Majeed syndrome 
• Deficiency of interleukin-1 receptor antagonist (DIRA) 
• Mevalonic aciduria 
Nonhereditary or polygenic disorders:  
• Adult-onset Still’s disease (AOSD) and Systemic-onset juvenile idiopathic arthritis (sJIA) 
• Syndrome of periodic fever, aphthous stomatitis, pharyngitis and adenitis (PAPAS, PFAPA 
syndrome) 
• Schnitzler syndrome 
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• Other proposed autoinflammatory diseases: Behçet’s disease, psoriatic arthritis, Crohn’s 
disease, Sweet’s syndrome, relapsing polychondritis, urticarial vasculitis, etc. 
 
	
